Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on January 09, 2017, 11:08:07 am

Title: AbbVie’s Glecaprevir/Pibrentasvir Cures Genotype 1 of Hep C at High Rates
Post by: Hep Editors on January 09, 2017, 11:08:07 am

AbbVie’s investigational, once-daily, fixed-dose combination tablet glecaprevir/pibrentasvir, known as G/P, cured those with genotype 1 of hepatitis C virus (HCV) at high rates in a recent large trial, aidsmap reports. The pangenotypic treatment (meaning it works on all genotypes of hep C) will likely gain approval from the U.S. Food and Drug Administration (FDA) in 2017.
 
Researchers from the Phase III ENDURANCE-1 trial of 703 people with genotype 1 of hep C presented findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

For more information...
https://www.hepmag.com/article/abbvies-glecaprevirpibrentasvir-cures-genotype-1-hep-c-high-rates

Title: Re: AbbVie’s Glecaprevir/Pibrentasvir Cures Genotype 1 of Hep C at High Rates
Post by: elias on January 09, 2017, 09:03:41 pm

Very good news.

I'm still unclear if the "breakthrough" FDA approval track is for GT 1 only? Since the Phase III Endurance 2-4 series show amazing cure rates for GT 2, 3 and 4 as well. So hopefully, approval will be cross-genotype as well

The AbbVie  glecaprevir/pibrentasvir regimen seems on a par with even Gilead's pan-genotypic Epclusa . And similar in its low side effects. It's also promising as a "salvage" treatment for retreating previous DAA failures. Wonder if this competition might force lower prices in Gilead's drugs?